| abstract |
1. Use of the compound according to the formula (LXVII)! ! wherein ! R21 is aralkyl or heteroaralkyl optionally substituted; ! R22 is aryl or heteroaralkyl optionally substituted; and! X represents O or S; ! and their pharmaceutically acceptable salts,! to obtain a drug that reduces cell replication, for the treatment, improvement or prevention of diseases, conditions and / or disorders. ! 2. The use according to claim 1, wherein R21 is benzyl, optionally substituted, and R22 is aryl, optionally substituted. ! 3. The use according to claim 1 or 2, in which R21 has a structure corresponding to the formula (LXVIII)! ! R23, R24, R25, R26 and R27 independently of one another are H, halogen, CN; NO2; NR′R ′ ′; alkyl, alkenyl, alkynyl; alkoxy, alkoxyalkyl; -OOC-R ′ ′ ′; -COO-R ′ ′ ′ ′ ′; aryl, heteroaryl optionally substituted; ! where R ′ and R ″ independently of one another are a hydrogen atom, alkyl, alkenyl or alkynyl, aryl or heteroaryl; optionally substituted; ! R ″ ″ means alkyl, alkenyl, alkynyl optionally substituted; and! R ″ ″ ″ means hydrogen, alkyl, alkenyl, alkynyl, in particular C1-C6 alkyl, for example C1, C2, C3, C4, C5 or C6 alkyl optionally substituted; ! or two or more substituents R23, R24, R25, R26 and R27 taken together form a cycloalkyl, heterocycloalkyl, alicyclic ring system, aryl or heteroaryl, optionally substituted; and! q means the integer 1.! 4. The use according to claim 3, in which R23, R24 and R27 mean N.! 5. The use according to claim 1, in which R22 has a structure corresponding to the formula (LXX)! ! wherein ! R31, R32, R33, R34 and R35 independently of one another are H, halogen, CN; NO2; NR′R ′ ′; alkyl, alkenyl, alkynyl; alcohol |